check_circleStudy Completed

Healthy Volunteers

Bayer Identifier:

16353

ClinicalTrials.gov Identifier:

NCT02119221

EudraCT Number:

2013-002544-90

EU CT Number:

Not Available
Copanlisib Mass Balance Study

Trial purpose

The study aims to provide understanding of the relative relevance of the different excretion pathways of Copanlisib in humans, as well as to characterize its metabolite profile.

Key Participants Requirements

Sex

Male

Age

45 - 65 Years
  • - Healthy male subject
    - Age: 45 to 65 years
    - Body weight greater or equal to 60 kg and body mass index (BMI): above/equal 18 and below/equal 30 kg/m²
  • - Regular use of medicines
    - Known recent (last 2 years) abuse of recreational drugs, suspicion of drug or alcohol abuse, or positive results of the drug and alcohol screen tests at screening or baseline
    - Use of strong inhibitors of cytochrome P450 (CYP)3A4, as well as use of St John’s Wort or strong inducers of CYP3A4 prohibited from 14 days before the administration of study drug until discharge from the clinic
    - Smoking
    - Average intake of more than 24 units of alcohol per week; Regular daily consumption of more than 1 L of methylxanthine-containing beverages
    - Any condition, which may result in longer than usual retention of urine or feces in the body, such as pronounced (less than one defecation in 2 days) constipation or symptomatic prostatic hypertrophy.
    - Participation in another mass balance study with a radiation burden > 0.1 mSv in the period of 1 year before screening

Trial summary

Enrollment Goal
6
Trial Dates
February 2014 - October 2014
Phase
Phase 1
Could I Receive a placebo
No
Products
Aliqopa (Copanlisib, BAY80-6946)
Accepts Healthy Volunteer
Yes

Where to participate

StatusInstitutionLocation
Completed
Pharma Bio-ResearchZuidlaren, 9471 GP, Netherlands

Primary Outcome

  • Pharmacokinetics of copanlisib in plasma by maximum concentration (Cmax)
    date_rangeTime Frame:
    Multiple time points up to 336 hours
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics of copanlisib in plasma by area under the measured matrix concentration versus time curve from the first time point (t=0) extrapolated to infinity (AUC)
    date_rangeTime Frame:
    Multiple time points up to 336 hours
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics of copanlisib in plasma by area under the measured matrix concentration versus time curve to the last data point above the lower limit of quantitation (AUC(0-tlast))
    date_rangeTime Frame:
    Multiple time points up to 336 hours
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics of total radioactivity in plasma by Cmax
    date_rangeTime Frame:
    Multiple time points up to 336 hours
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics of total radioactivity in plasma by AUC
    date_rangeTime Frame:
    Multiple time points up to 336 hours
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics of total radioactivity in plasma by AUC(0-tlast)
    date_rangeTime Frame:
    Multiple time points up to 336 hours
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics of total radioactivity in whole blood by Cmax
    date_rangeTime Frame:
    Multiple time points up to 336 hours
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics of total radioactivity in whole blood by AUC
    date_rangeTime Frame:
    Multiple time points up to 336 hours
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics of total radioactivity in whole blood by AUC(0-tlast)
    date_rangeTime Frame:
    Multiple time points up to 336 hours
    enhanced_encryption
    Safety Issue:
    No
  • Radioactivity excreted in urine as a percentage of the dose (AE,ur)
    date_rangeTime Frame:
    Multiple time points up to 336 hours
    enhanced_encryption
    Safety Issue:
    No
  • Radioactivity excreted in feces as a percentage of the dose (AE,fec)
    date_rangeTime Frame:
    Multiple time points up to 336 hours
    enhanced_encryption
    Safety Issue:
    No
  • Metabolite profile in plasma
    date_rangeTime Frame:
    Multiple time points up to 336 hours
    enhanced_encryption
    Safety Issue:
    No
  • Metabolite profile in urine
    date_rangeTime Frame:
    Multiple time points up to 336 hours
    enhanced_encryption
    Safety Issue:
    No
  • Metabolite profile in feces
    date_rangeTime Frame:
    Multiple time points up to 336 hours
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • Number of participants with adverse events as a measure of safety and tolerability
    date_rangeTime Frame:
    Until 30 days after study drug administration
    enhanced_encryption
    Safety Issue:
    Yes

Trial design

Single center, open-label, non-randomized, non-placebo-controlled study to investigate the metabolism, excretion pattern, mass balance, safety, tolerability and pharmacokinetics after single intravenous administration of 12 mg [14C]Copanlisib (BAY 80-6946) in healthy male subjects
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Basic Science
Allocation
N/A
Blinding
Open Label
Assignment
Single Group Assignment
Trial Arms
1

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.